NCT06862596View on ClinicalTrials.gov

Clinical Trial of Mexiletine Hydrochloride for Spinal and Bulbar Muscular Atrophy

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Spinal and Bulbar Muscular Atrophy
Interventions
DRUG

Mexiletine hydrochloride

Mexiletine hydrochloride 300 mg is administered orally divided into three times a day after meals for 12 weeks.

OTHER

Placebo

Placebo is administered orally divided into three times a day after meals for 12 weeks.

Trial Locations (5)

Unknown

RECRUITING

Tokyo University Hospital, Bunkyō City

RECRUITING

Chiba University Hospital, Chiba

RECRUITING

Hokkaido University Hospital, Sapporo

RECRUITING

Jichi Medical University Hospital, Shimotsuke

RECRUITING

Osaka University Hospital, Suita

All Listed Sponsors
lead

Masahisa Katsuno

OTHER